Development of a ten-signature classifier using a support vector machine integrated approach to subgroup the M1 stage into M1a and M1b stages of nasopharyngeal carcinoma with synchronous metastases to better predict patients’ survival

Rou Jiang1,2,3,*, Rui You1,2,*, Xiao-Qing Pei4,*, Xiong Zou1,2,*, Meng-Xia Zhang1,2, Tong-Min Wang2, Rui Sun1,2, Dong-Hua Luo1,2, Pei-Yu Huang1,2, Qiu-Yan Chen1,2, Yi-Jun Hua1,2, Lin-Quan Tang1,2, Ling Guo1,2, Hao-Yuan Mo1,2, Chao-Nan Qian1,2, Hai-Qiang Mai1,2, Ming-Huang Hong2,5, Hong-Min Cai6 and Ming-Yuan Chen1,2

1 Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China
2 Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China
3 Department of Cancer Prevention, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China
4 Department of Ultrasonography, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China
5 Department of Clinical Trials Center, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China
6 School of Computer and Engineering, South China University of Technology, Guangzhou, P. R. China

* These authors have contributed equally to this study

Correspondence to: Ming-Yuan Chen, email: chmingy@mail.sysu.edu.cn
Correspondence to: Hong-Min Cai, email: hmcai@scut.edu.cn

Keywords: nasopharyngeal carcinoma, synchronous metastases, support vector machine, prognosis, therapy

Received: August 04, 2015 Accepted: November 16, 2015 Published: November 30, 2015

ABSTRACT

The aim of this study was to develop a prognostic classifier and subdivided the M1 stage for nasopharyngeal carcinoma patients with synchronous metastases (mNPC). A retrospective cohort of 347 mNPC patients was recruited between January 2000 and December 2010. Thirty hematological markers and 11 clinical characteristics were collected, and the association of these factors with overall survival (OS) was evaluated. Advanced machine learning schemes of a support vector machine (SVM) were used to select a subset of highly informative factors and to construct a prognostic model (mNPC-SVM). The mNPC-SVM classifier identified ten informative variables, including three clinical indexes and seven hematological markers. The median survival time for low-risk patients (M1a) as identified by the mNPC-SVM classifier was 38.0 months, and survival time was dramatically reduced to 13.8 months for high-risk patients (M1b) \( (P < 0.001) \). Multivariate adjustment using prognostic factors revealed that the mNPC-SVM classifier remained a powerful predictor of OS (M1a vs. M1b, hazard ratio, 3.45; 95% CI, 2.59 to 4.60, \( P < 0.001 \)). Moreover, combination treatment of systemic chemotherapy and loco-regional radiotherapy was associated with significantly better survival outcomes than chemotherapy alone (the 5-year OS, 47.0% vs. 10.0%, \( P < 0.001 \)) in the M1a subgroup but not in the M1b subgroup (12.0% vs. 3.0%, \( P = 0.101 \)). These findings were validated by a separate cohort. In conclusion, the newly developed mNPC-SVM classifier led to more precise risk definitions that offer a promising subdivision of the M1 stage and individualized selection for future therapeutic regimens in mNPC patients.
INTRODUCTION

Nasopharyngeal carcinoma (NPC) is a distinct malignancy of the head and neck with a high incidence (4%-6%) of distant metastases [1-3]. Metastatic NPC is incurable and devastating, with a median survival of ten to fifteen months using palliative systemic chemotherapy[4]. The current American Joint Committee on Cancer (AJCC/UICC) Tumor, Node, and Metastasis (TNM) staging uses “M1” to denote the TNM stage for all patients with distant metastasis. Therefore, TNM staging ignores the heterogeneity between patients, and this system may exhibit reduced critical accuracy in patients with distant metastases [1, 5, 6]. NPC patients exhibit common clinical characteristics, such as tumor volume and number, and numerous molecular and hematological markers are also useful to predict outcomes of NPC patients, especially the microcosmic aspect of patients. Compared with molecular markers, hematological markers are more easily applicable to clinical practice because of its convenience and availability.

Palliative chemotherapy benefits the survival of newly diagnosed NPC patients with synchronous distant metastases (mNPC). Previous studies reported improved overall survival (OS) with loco-regional radiotherapy combined with chemotherapy in mNPC patients compared with chemotherapy alone [7]. However, the TNM classification system does not identify which patients should undergo palliative chemotherapy alone or combination treatment. Consequently, it is difficult for clinicians to choose the most suitable treatment for mNPC patients.

The above-mentioned facts prompted us to develop a novel prognostic model based on the clinical characteristics and hematological markers for mNPC patients to correctly predict the survival of mNPC patients and aid clinicians in treatment planning.

RESULTS

Patient characteristics

The baseline of patients’ clinical features of the primary cohort and validation cohort were displayed in Table 1. In the primary cohort, patients ranged from 13 to 78 years old (median age, 48 years), and 80% were male. Bone was the most common site of metastasis (66.0%), followed by liver (38.0%) and lung (20.0%). Most patients exhibited multiple sites of metastases at the time of diagnosis (81.0%). The median survival was 22.6 months (range, 3.2–164.3 months). A total of 269 (78.0%) of the 347 patients had died by the last follow-up. The OS rates at 1, 2, 3 and 5 years were 76%, 46%, 31%, and 22%, respectively (data not shown).

Combinational prognostic model via RFE-SVM analysis

Experiments of the entire dataset using RFE-SVM analysis identified ten informative variables, including three clinical indexes (oligometastases, N stage, and extraregional lymph node metastasis) and seven hematological markers (EB-VCA IgA, neutrophil count, monocyte count, platelet count, hemoglobin, glutamic-pyruvic transaminase, and glutamyltranspetidase). The ROC curves for each of the ten selected variables and their combination, the mNPC-SVM classifier, illustrated the maximum area under the curve (AUC) for each factor. The AUC for the mNPC-SVM classifier was significantly greater than the AUCs for all other individual prognostic factors (0.761, Figure 1). The specificity and sensitivity of mNPC-SVM were 71.3% and 80.7%, respectively. Significant association was observed between the mNPC-SVM and N stage, metastatic organ/lesion involvement and oligometastases by Spearman correlation analysis (Table 2). In the validation cohort, the AUC for the mNPC-SVM classifier was 0.633 (Supplemental Figure 1).

Subdivision of the M1 stage using the mNPC-SVM classifier and overall survival

The mNPC-SVM classifier identified 182 patients as low risk (called the M1a stage) and 165 patients as high risk (defined as the M1b stage). The 2-year overall survival rates differed significantly between M1a and M1b patients (71.4% v 18.8%, P < 0.001). The corresponding overall survival also differed significantly. The median survival time for the low-risk patient group was 38.0 months, and survival time for the high-risk patient group was dramatically reduced to 13.8 months (P < 0.001, Figure 2). A similar trend was also observed in the validation cohort (P = 0.001, Supplemental Figure 2).

Selection of independent prognostic factors of survival

Univariate analysis of the 347 mNPC patients using the mNPC-SVM classifier revealed an apparent association of 5 clinical indexes with OS (Table 3). The mNPC-SVM classifier remained a powerful predictor of OS after multivariate adjustment using clinicopathological characteristics (predicted low risk vs. predicted high risk, hazard ratio, 3.45; 95% CI, 2.59 to 4.60; P < 0.001). By contrast, there was no significant difference in OS after multivariate adjustment by N stage, metastatic organ/lesion involvement, liver metastasis or extraregional lymph node metastasis (Table 4).
| Parameters                          | Primary cohort | Validation cohort |
|------------------------------------|----------------|-------------------|
|                                    | n=347          | n=106             |
| Sex                                |                |                   |
| Female                             | 69             | 23                |
| Male                               | 278            | 83                |
| Age                                |                |                   |
| < 48 years                         | 173            | 55                |
| ≥ 48 years                         | 174            | 51                |
| T Classification*                  |                |                   |
| T1-2                               | 142            | 22                |
| T3-4                               | 205            | 84                |
| N Classification*                  |                |                   |
| N0-1                               | 134            | 25                |
| N2-3                               | 213            | 81                |
| No. of metastatic organs           |                |                   |
| Single                             | 242            | 81                |
| Multiple                           | 105            | 25                |
| No. of metastatic lesions          |                |                   |
| Single                             | 65             | 34                |
| Multiple                           | 282            | 72                |
| Oligometastases                    |                |                   |
| No                                 | 132            | 44                |
| Yes                                | 215            | 62                |
| Bony metastasis                    |                |                   |
| Absent                             | 118            | 32                |
| Present                            | 229            | 74                |
| Liver metastasis                   |                |                   |
| Absent                             | 216            | 73                |
| Present                            | 131            | 33                |
| Lung metastasis                    |                |                   |
| Absent                             | 278            | 82                |
| Present                            | 69             | 24                |
| Extraregional lymph node metastasis|                |                   |
| Absent                             | 299            | 100               |
| Present                            | 48             | 6                 |
| Anticancer treatment               |                |                   |
| Systemic chemotherapy alone        | 161            | 40                |
| Chemotherapy plus radiotherapy     | 174            | 65                |
| Radiotherapy alone                 | 12             | 1                 |

*According to Union for International Cancer Control / American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002).
Figure 1: Receiver operating characteristic (ROC) curves for each of the selected ten variables and their combination, the mNPC-SVM classifier, as predictors of death as a result of mNPC within 2 years.

Figure 2: Kaplan–Meier survival analysis of the mNPC-SVM classifier in nasopharyngeal carcinoma patients with synchronous metastases (mNPC).

Figure 3: Kaplan–Meier survival analysis of treatment modality in nasopharyngeal carcinoma patients with synchronous metastases (mNPC) regarding the mNPC-SVM classifier. CRT, chemoradiotherapy; SCT, systemic chemotherapy alone.
The mNPC-SVM classifier is an outstanding indicator for the treatment choice

The efficacy of different treatment modalities was also investigated. Fifty-nine of the 182 patients identified as low risk were treated using systemic chemotherapy alone (SCT), 118 patients were treated using chemoradiotherapy (CRT), and 5 patients were treated using radiotherapy (RT). The 1-, 2-, 3- and 5-year OS rates in the SCT and CRT groups were 57.0% vs. 68.0%, 18.0% vs. 21.0%, 6.0% vs. 15.0%, and 3.0% vs. 12.0%, respectively (\(P = 0.101\)) (Figure 3B). In the validation cohort, CRT was also associated with significantly better survival outcomes than SCT in the M1a subgroup but not in the M1b subgroup (Supplemental Figure 3).

**DISCUSSION**

TNM staging system is an excellent staging system for NPC patients. However, all patients with distant metastasis are staged as M1, which ignores the

| Parameters                              | mNPC-SVM classifier | \(r\) value | \(p\) value |
|-----------------------------------------|---------------------|-------------|-------------|
| Sex                                     |                     |             |             |
| Female                                  | 38                  | 31          | -0.026      | 0.627       |
| Male                                    | 144                 | 134         |             |             |
| Age                                     |                     |             |             |
| < 48 years                              | 95                  | 78          | 0.049       | 0.361       |
| \(\geq 48\) years                      | 87                  | 87          |             |             |
| T Classification*                       |                     |             |             |
| T1-2                                    | 76                  | 66          | 0.018       | 0.740       |
| T3-4                                    | 106                 | 99          |             |             |
| N Classification*                       |                     |             |             |
| N0-1                                    | 88                  | 46          | 0.21        | <0.001      |
| N2-3                                    | 94                  | 119         |             |             |
| No. of metastatic organs                |                     |             |             |
| Single                                  | 142                 | 100         | 0.189       | <0.001      |
| Multiple                                | 40                  | 65          |             |             |
| No. of metastatic lesions               |                     |             |             |
| Single                                  | 49                  | 16          | 0.220       | <0.001      |
| Multiple                                | 133                 | 149         |             |             |
| Oligometastases                          |                     |             |             |
| No                                      | 56                  | 76          | -0.157      | 0.003       |
| Yes                                     | 126                 | 89          |             |             |
| Bony metastasis                         |                     |             |             |
| Absent                                  | 67                  | 51          | 0.062       | 0.248       |
| Present                                 | 115                 | 114         |             |             |
| Liver metastasis                        |                     |             |             |
| Absent                                  | 122                 | 94          | 0.104       | 0.054       |
| Present                                 | 60                  | 71          |             |             |
| Lung metastasis                         |                     |             |             |
| Absent                                  | 147                 | 131         | 0.017       | 0.749       |
| Present                                 | 35                  | 34          |             |             |
| Extraregional lymph node metastasis     |                     |             |             |
| Absent                                  | 161                 | 138         | 0.070       | 0.195       |
| Present                                 | 21                  | 27          |             |             |

*According to Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002).

**The mNPC-SVM classifier is an outstanding indicator for the treatment choice**
Table 3: Univariate analysis of clinicopathological and hematological characteristics

| Variables                        | Patients (N =347) | 2-Year OS (95% CI) | Unadjusted HR (95% CI) | P     |
|----------------------------------|-------------------|-------------------|------------------------|-------|
| mNPC -SVM classifier             |                   |                   |                        |       |
| Predicted low risk               | 182.00            | 0.71 (0.51-0.91)  | Reference              |       |
| Predicted high risk              | 165.00            | 0.19 (0.17, 0.21) | 3.71 (2.88, 4.79)      | <0.001|
| Sex                              |                   |                   |                        |       |
| Male                             | 278.00            | 0.46 (0.40, 0.52) | Reference              |       |
| Female                           | 69.00             | 0.48 (0.34, 0.62) | 0.84 (0.62, 1.14)      | 0.269 |
| Age                              |                   |                   |                        |       |
| < 48 years                       | 173.00            | 0.48 (0.39, 0.57) | Reference              |       |
| ≥ 48 years                       | 174.00            | 0.45 (0.37, 0.53) | 1.07 (0.84, 1.36)      | 0.592 |
| T Classification*                |                   |                   |                        |       |
| T1-2                             | 142.00            | 0.46 (0.37, 0.55) | Reference              |       |
| T3-4                             | 205.00            | 0.46 (0.39, 0.53) | 0.94 (0.74, 1.20)      | 0.626 |
| N Classification*                |                   |                   |                        |       |
| N0-1                             | 134.00            | 0.57 (0.44, 0.70) | Reference              |       |
| N2-3                             | 213.00            | 0.39 (0.33, 0.45) | 1.38 (1.21, 1.57)      | <0.001|
| No. of metastatic organs         |                   |                   |                        |       |
| Single                           | 242.00            | 0.53 (0.44, 0.62) | Reference              |       |
| Multiple                         | 105.00            | 0.30 (0.25, 0.35) | 1.72 (1.33, 2.21)      | <0.001|
| No. of metastatic lesions        |                   |                   |                        |       |
| Single                           | 65.00             | 0.60 (0.38, 0.82) | Reference              |       |
| Multiple                         | 282.00            | 0.43 (0.37, 0.49) | 1.82 (1.31, 2.55)      | <0.001|
| Oligometastases                  |                   |                   |                        |       |
| No                               | 132.00            | 0.48 (0.38, 0.58) | Reference              |       |
| Yes                              | 215.00            | 0.46 (0.39, 0.53) | 0.92 (0.72, 1.18)      | 0.530 |
| Bony metastasis                  |                   |                   |                        |       |
| Absent                           | 118.00            | 0.45 (0.35, 0.55) | Reference              |       |
| Present                          | 229.00            | 0.47 (0.40, 0.54) | 0.89 (0.69, 1.14)      | 0.359 |
| Liver metastasis                 |                   |                   |                        |       |
| Absent                           | 216.00            | 0.53 (0.44, 0.62) | Reference              |       |
| Present                          | 131.00            | 0.35 (0.39, 0.41) | 1.56 (1.22, 1.99)      | <0.001|
| Lung metastasis                  |                   |                   |                        |       |
| Absent                           | 278.00            | 0.46 (0.40, 0.52) | Reference              |       |
| Present                          | 69.00             | 0.46 (0.31, 0.61) | 1.11 (0.82, 1.47)      | 0.530 |
| Extraregional lymph node metastasis|                 |                   |                        |       |
| Absent                           | 299.00            | 0.48 (0.41, 0.55) | Reference              |       |
| Present                          | 48.00             | 0.36 (0.25, 0.47) | 1.21 (1.03, 1.43)      | 0.022 |
| EB-VCAlgA                        |                   |                   |                        |       |
| ≤1:160                           | 116.00            | 0.39 (0.32, 0.46) | Reference              |       |
| >1:160                           | 231.00            | 0.50 (0.42, 0.58) | 0.97 (0.75, 1.25)      | 0.790 |
| EB-EAlgA                         |                   |                   |                        |       |
| ≤1:10                            | 106.00            | 0.42 (0.33, 0.51) | Reference              |       |
| >1:10                            | 241.00            | 0.49 (0.42, 0.56) | 0.90 (0.70, 1.17)      | 0.904 |
| White cell count (per 109 cells/l)|                 |                   |                        |       |
| ≤7.75                            | 197.00            | 0.53 (0.43, 0.63) | Reference              |       |
| >7.75                            | 150.00            | 0.38 (0.32, 0.44) | 1.39 (1.09, 1.76)      | 0.008 |
| Parameter                          | ≤ Value | Mean (95% CI) | Reference | p Value |
|-----------------------------------|---------|---------------|-----------|---------|
| Percentage of neutrophils         | ≤0.6825 | 208.00 0.54 (0.44, 0.64) | Reference | <0.001 |
|                                   | >0.6825 | 139.00 0.35 (0.29, 0.41) | 2.39 (1.87, 3.05) | <0.001 |
| Neutrophil count (per 109 cells/l)| ≤4.685  | 166.00 0.55 (0.43, 0.67) | Reference | <0.001 |
|                                   | >4.685  | 181.00 0.38 (0.32, 0.44) | 1.54 (1.21, 1.96) | <0.001 |
| Percentage of lymphocytes         | ≤0.2255 | 149.00 0.32 (0.27, 0.37) | Reference | <0.001 |
|                                   | >0.2255 | 198.00 0.57 (0.46, 0.68) | 0.45 (0.35, 0.57) | <0.001 |
| Lymphocyte count (per 109 cells/l)| ≤2.005  | 230.00 0.42 (0.36, 0.48) | Reference | <0.001 |
|                                   | >2.005  | 117.00 0.55 (0.42, 0.68) | 0.63 (0.49, 0.83) | <0.001 |
| Percentage of monocytes           | ≤0.0765 | 173.00 0.58 (0.46, 0.70) | Reference | <0.001 |
|                                   | >0.0765 | 174.00 0.35 (0.30, 0.40) | 1.77 (1.39, 2.25) | <0.001 |
| Monocyte count (per 109 cells/l)  | ≤0.5964 | 157.00 0.68 (0.50, 0.86) | Reference | <0.001 |
|                                   | >0.5964 | 190.00 0.29 (0.25, 0.34) | 2.45 (1.91, 3.15) | <0.001 |
| Red blood cell count (per 1012 cells/l) | ≤4.355 | 132.00 0.26 (0.22, 0.30) | Reference | <0.001 |
|                                   | >4.355  | 215.00 0.59 (0.48, 0.70) | 0.46 (0.36, 0.59) | <0.001 |
| Hemoglobin (g/l)                  | ≤129.6  | 134.00 0.23 (0.20, 0.26) | Reference | <0.001 |
|                                   | >129.6  | 213.00 0.61 (0.49, 0.73) | 0.42 (0.33, 0.54) | <0.001 |
| Platelet count (per 109 cells/l)  | ≤287    | 261.00 0.50 (0.42, 0.58) | Reference | <0.001 |
|                                   | >287    | 86.00 0.36 (0.28, 0.44) | 1.58 (1.21, 2.07) | <0.001 |
| Albumin (g/l)                     | ≤40.55  | 95.00 0.24 (0.20, 0.28) | Reference | <0.001 |
|                                   | >40.55  | 252.00 0.55 (0.46, 0.64) | 0.40 (0.30, 0.51) | <0.001 |
| Globulin (g/l)                    | ≤31.95  | 168.00 0.56 (0.44, 0.68) | Reference | <0.001 |
|                                   | >31.95  | 179.00 0.37 (0.31, 0.43) | 1.65 (1.29, 2.10) | <0.001 |
| Albumin/globulin ratio            | ≤1.34   | 160.00 0.34 (0.29, 0.39) | Reference | <0.001 |
|                                   | >1.34   | 187.00 0.57 (0.45, 0.69) | 0.50 (0.39, 0.64) | <0.001 |
| Total protein (g/l)               | ≤65.5   | 28.00 0.25 (0.17, 0.33) | Reference | <0.001 |
|                                   | >65.5   | 319.00 0.48 (0.42, 0.54) | 0.49 (0.33, 0.73) | <0.001 |
| AST (u/l)                         | ≤32.8   | 274.00 0.52 (0.44, 0.60) | Reference | <0.001 |
|                                   | >32.8   | 73.00 0.25 (0.20, 0.30) | 2.27 (1.71, 3.00) | <0.001 |
| **ALT (u/l)** | **≤54.5** | **>54.5** | **AST/ALT** |
|---------------|-----------|-----------|-------------|
|               | 313.00    | 34.00     | 0.49 (0.42, 0.56) | **Reference** |
| **≤54.5**     | 0.49 (0.42, 0.56) | 1.69 (1.15, 2.48) | 0.008 |
| **>54.5**     | 0.24 (0.18, 0.30) | 1.44 (1.12, 1.83) | 0.004 |

| **AST/ALT** |
|-------------|
| **≤1.21**   | 216.00    | 0.52 (0.43, 0.61) | **Reference** |
| **>1.21**   | 131.00    | 0.37 (0.30, 0.44) | 1.69 (1.15, 2.48) | 0.008 |

| **ALP (u/l)** |
|---------------|
| **≤86.95**    | 177.00    | 0.63 (0.48, 0.78) | **Reference** |
| **>86.95**    | 170.00    | 0.29 (0.25, 0.33) | 2.42 (1.89, 3.09) | <0.001 |

| **GGT (u/l)** |
|---------------|
| **≤66**       | 274.00    | 0.54 (0.45, 0.63) | **Reference** |
| **>66**       | 73.00     | 0.19 (0.16, 0.22) | 2.35 (1.77, 3.11) | <0.001 |

| **AST/ALT** |
|-------------|
| **≤1.21**   | 216.00    | 0.52 (0.43, 0.61) | **Reference** |
| **>1.21**   | 131.00    | 0.37 (0.30, 0.44) | 1.69 (1.15, 2.48) | 0.008 |

| **LDH (u/l)** |
|---------------|
| **≤186.5**    | 125.00    | 0.70 (0.46, 0.94) | **Reference** |
| **>186.5**    | 222.00    | 0.33 (0.29, 0.37) | 2.76 (2.10, 3.62) | <0.001 |

| **AFU (u/l)** |
|---------------|
| **≤13.95**    | 78.00     | 0.56 (0.48, 0.74) | **Reference** |
| **>13.95**    | 269.00    | 0.43 (0.37, 0.49) | 0.90 (0.68, 1.19) | 0.447 |

| **TBIL (µmol/l)** |
|-------------------|
| **≤11.65**        | 197.00    | 0.36 (0.31, 0.41) | **Reference** |
| **>11.65**        | 150.00    | 0.60 (0.44, 0.74) | 0.56 (0.43, 0.71) | <0.001 |

| **DBIL (µmol/l)** |
|-------------------|
| **≤2.885**        | 117.00    | 0.38 (0.31, 0.45) | **Reference** |
| **>2.885**        | 230.00    | 0.51 (0.43, 0.59) | 0.70 (0.55, 0.90) | 0.005 |

| **IBIL (µmol/l)** |
|-------------------|
| **≤7.935**        | 195.00    | 0.34 (0.29, 0.39) | **Reference** |
| **>7.935**        | 152.00    | 0.62 (0.47, 0.77) | 0.56 (0.44, 0.71) | <0.001 |

| **HDL-C (mmol/l)** |
|--------------------|
| **≤0.995**         | 119.00    | 0.28 (0.24, 0.32) | **Reference** |
| **>0.995**         | 228.00    | 0.56 (0.46, 0.66) | 0.49 (0.38, 0.63) | <0.001 |

| **LDL-C (mmol/l)** |
|--------------------|
| **≤3.2475**        | 214.00    | 0.43 (0.37, 0.49) | **Reference** |
| **>3.2475**        | 133.00    | 0.51 (0.39, 0.63) | 0.72 (0.56, 0.93) | 0.011 |

| **ApoA-I (g/l)** |
|------------------|
| **≤1.1575**      | 159.00    | 0.31 (0.26, 0.36) | **Reference** |
| **>1.1575**      | 188.00    | 0.59 (0.47, 0.61) | 0.47 (0.37, 0.60) | <0.001 |

| **Apo B (g/l)** |
|-----------------|
| **≤1.045**      | 220.00    | 0.44 (0.38, 0.50) | **Reference** |
| **>1.045**      | 127.00    | 0.51 (0.39, 0.63) | 0.90 (0.70, 1.15) | 0.401 |

Abbreviations: AST: aspartate aminotransferase; ALT: glutamic-pyruvic transaminase; ALP: alkaline phosphatase; GGT: glutaminyltranspeptidase; LDH: lactate dehydrogenase; AFU: alpha-fucosidase; TBIL: total bilirubin; DBIL: direct bilirubin; IBIL: indirect bilirubin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA-I: Apolipoprotein A-I; Apo B: Apolipoprotein B; *According to Union for International Cancer Control /American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002).
heterogeneity between patients. M1 staging may not be a good prognostic value for survival outcome or a good indicator of treatment choice for mNPC patients. Various specially designed prognostic models reportedly demonstrate enhanced prognostic value for patients with distant metastasis [8, 9]. However, no further aid for clinicians' choice of the most suitable treatment for these recurrent patients was evident. Therefore, we developed a novel ten-signature mNPC-SVM classifier to categorize patients with mNPC into high- and low-risk groups. The survival curves were distinctly separate between these two groups. The mNPC-SVM classifier was a significant independent prognostic factor for OS. ROC analyses also suggested that the mNPC-SVM exhibited a better prognostic value than the single indexes or markers. Chemotherapy plus radiotherapy was also associated with

| Table 4: Multivariate of clinicopathological characteristics |
|-------------------|-----------------|-----|
| Variables         | Adjusted HR (95%CI) | P   |
| mNPC -SVM classifier |                  |     |
| Predicted low risk | Reference        |     |
| Predicted high risk | 3.45 (2.59, 4.60) | < 0.001 |
| Sex               |                  |     |
| Male              | Reference        |     |
| Female            | 0.90 (0.65, 1.24) | 0.517 |
| Age               |                  |     |
| < 48 years        | Reference        |     |
| ≥ 48 years        | 1.06 (0.83, 1.36) | 0.643 |
| T Classification* |                  |     |
| T1-2              | Reference        |     |
| T3-4              | 0.97 (0.85, 1.11) | 0.642 |
| N Classification* |                  |     |
| N0-1              | Reference        |     |
| N2-3              | 1.13 (0.86, 1.48) | 0.389 |
| No. of metastatic organs |          |     |
| Single            | Reference        |     |
| Multiple          | 1.44 (0.82, 2.55) | 0.206 |
| No. of metastatic lesions |        |     |
| Single            | Reference        |     |
| Multiple          | 1.34 (0.85, 2.13) | 0.210 |
| Oligometastases   |                  |     |
| No                | Reference        |     |
| Yes               | 1.06 (0.71, 1.60) | 0.765 |
| Bony metastasis   |                  |     |
| Absent            | Reference        |     |
| Present           | 0.74 (0.48, 1.15) | 0.185 |
| Liver metastasis  |                  |     |
| Absent            | Reference        |     |
| Present           | 1.02 (0.66, 1.58) | 0.936 |
| Lung metastasis   |                  |     |
| Absent            | Reference        |     |
| Present           | 0.67 (0.41, 1.10) | 0.116 |
| Extraregional lymph node metastasis |      |     |
| Absent            | Reference        |     |
| Present           | 1.11 (0.88, 1.39) | 0.380 |

*According to Union for International Cancer Control /American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002).
an enhanced survival benefit for M1 patients with low risk compared with systemic chemotherapy alone. However, a statistically significant difference was not observed in the CRT group compared with the SCT group for high-risk M1 patients with. M1 stage with low risk was defined as M1a, and M1 stage with high risk was considered M1b.

A single index or marker did not comprehensively reflect patient status. Therefore, our model is not a perfect prognostic model. Univariate analysis and traditional statistics are limited because they ignore the role of combinational potentials that may provide a good prediction of patient survival outcomes. Therefore, machine-learning methods were introduced in cancer classification and prediction because of their powerful capabilities in allowing inferences or decisions to be made that could not otherwise be made using conventional statistical methodologies [10-12]. Support vector machines (SVMs) are one of the most effective and widely used machine-learning techniques in the field of cancer prediction and prognosis [10, 13, 14]. The SVM algorithm creates a hyperplane that separates the data into two classes with the maximum margin, which is obtained by calculating the distance between the hyperplane and the closest examples or the margin. The application of different kernels to different data sets can dramatically improve the performance of an SVM classifier.

We designed the SVM models for mNPC via integration of three clinical indexes and seven hematological markers, which reflected the tumorigenesis phenotype of each patient macroscopically and microscopically. Therefore, a multi-biomarker-based model would provide more powerful efficacy for the prediction of patient outcome compared with single clinical index or hematological markers. The factors included in the SVM are used routinely in clinical practice, and they are easily available, which makes the model practical and convenient.

Palliative systemic chemotherapy is the major treatment modality for NPC patients with distant metastasis at diagnosis [15, 16]. However, the results of chemotherapy as an initial monotherapy in NPC patients with distant metastasis at diagnosis are not satisfactory. By contrast, radiotherapy or surgery for the primary lesions combined with systemic chemotherapy is beneficial for the survival outcome of these patients with distant metastases. Immunootherapy combined with radical nephrectomy resulted in better survival outcomes over time to progression (5 vs. 3 months, hazard ratio 0.60, 95% CI 0.36-0.97) and median duration of survival (11.1-17 vs. 7-8.1 months, \( P \leq 0.05 \))[17, 18]. Morgan hypothesized that treatment directed against the primary tumor would retard the progression of existing metastases based on animal models and clinical observations [19]. Similarly, recent reports indicated that locoregional radiotherapy alone or combined with systemic chemotherapy was associated with improved survival of mNPC patients [7, 20]. However, these aggressive combination treatments may also result in adverse effects, especially treatment-related complications. Therefore, it is critical to identify patients who would benefit most from aggressive treatment modalities. The current study demonstrated that low-risk (M1a) patients exhibited better survival outcomes compared with high-risk (M1b) patients, but they were more suitable for systematic chemotherapy combined with loco-regional radiotherapy. However, locoregional radiotherapy combined with chemotherapy failed to exert significant survival benefits in high-risk (M1b) patients compared to systemic chemotherapy alone.

This retrospective design had several potential limitations. First, although we included the majority of common clinical indexes and hematological markers in the current study, there were other relative indexes that were not included in the study. Therefore, the mNPC-SVM classifier may be further improved by the inclusion of some proven prognostic markers. Second, the efficacy of the combination treatment in high-risk mNPC patients cannot be guaranteed because of differences in the use of loco-regional radiotherapy and systemic chemotherapy in different institutions. Therefore, an optimal combination treatment schedule should be suggested for clinicians to provide the greatest survival benefit to mNPC patients.

In conclusion, the mNPC-SVM classifier exhibited better prognostic value the clinical indexes alone or hematological markers for mNPC patient survival, and this model may aid clinicians’ selection of the most suitable treatment option for mNPC patients. However, we acknowledge that more studies are needed to validate this novel prognostic model.

**MATERIALS AND METHODS**

**Patient data collection**

The primary cohort of 347 mNPC patients for support vector machine (SVM) model development was derived from Sun Yat-sen University Cancer Center (SYSUCC) between January 2000 and December 2010. To examine the generalizability of the model, an validation cohort of 106 mNPC patients were included from SYSUCC between January 2011 and December 2012. Patients were excluded from the trial for any of the following criteria: 1) more than 3 months from the diagnosis of metastasis to pathological proof of NPC; 2) Karnofsky Performance Status score < 70; or 3) missing clinical/laboratory data. All patients were retrospectively classified into T1-4, N0-3, and M1 based on medical records using the Union for International Cancer Control /American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002). Bone metastasis was diagnosed based on patient history,
physical examination, and imaging studies using a bone scan and/or positron-emission tomography/computed tomography and/or magnetic resonance imaging (MRI). The diagnosis of liver metastasis was based on histological evaluation, ultrasound or computed tomography of the abdomen. Lung metastasis was routinely determined using chest X-ray and/or computed tomography (CT). Pathological confirmation using a biopsy was performed when X-ray and/or CT was insufficient to confirm lung metastasis. The Clinical Ethics Review Board at Cancer Center of Sun Yat-sen University approved this study.

**Treatment**

Cisplatin-based systemic chemotherapy was first provided to all patients as the basic treatment according to our institutional guideline for palliative treatment of mNPC. Definitive radiotherapy targeting of the primary tumor and its regional lymph nodes (locoregional radiotherapy, lrRT) was administered to some patients for local symptomatic treatment or as part of a multidisciplinary approach using two-dimensional conventional radiotherapy (2D-CRT) or intensity modulated radiotherapy (IMRT) as previously described [7, 21, 22].

**Patient follow-up**

Clinical follow-up visits with each patient were scheduled on a semiannual basis. The follow-up division in the information department of SYSUCC ascertained patient’s vital status, and follow-up information was updated until death from mNPC or the most recent follow-up, whichever occurred first. Causes of deaths were determined through death certificates, which were supplemented with medical records when necessary. The last follow-up dates were December 30, 2013 and June 30, 2015 for the primary and validation cohort respectively.

**Laboratory measurements**

Blood biochemistries of all patients were determined using a Hitachi Automatic Analyzer 7600-020 (Hitachi High-Technologies, Tokyo, Japan). Complete blood count (CBC) was determined using a fully automated hematology analyzer Sysmex XE-5000 (Sysmex, Kobe, Japan). The inclusive criterion for the hematological indexes was the easily accessed variables in clinics.

**Selection of cut-off scores**

The sensitivity and specificity of hematological markers as a predictor of death from mNPC within 2 years was plotted to generate a receiver operating characteristic (ROC) curve. We used 2-year OS as the outcome because median patient survival in this study was 22.6 months. ROC curves were used to select cut-off scores to dichotomize each predictor based on the score with the maximum area under the ROC curve (i.e., score nearest to a point on curve [0.0, 1.0] with maximum sensitivity and specificity).

**Statistical analysis**

**Univariate and multivariate analyses**

Statistical analysis was performed using SPSS software (version 16.0, SPSS Inc., Chicago, IL). OS was defined as the time interval from the first diagnosis of metastatic NPC to death or the most recent follow-up. Univariate and multivariate analyses of variables were performed using Cox proportional hazards regression models. Actuarial OS was plotted against time using the Kaplan–Meier method, and differences between survival curves were compared using the log-rank test. The correlation of mNPC-SVM model with different clinicopathologic characteristics was evaluated by Spearman’s rank correlation coefficient (r). The chi-square test was used to analyze differences in proportions. Statistical significance was defined as $P < 0.05$.

**Prognostic analysis of survival status using machine learning modeling**

CBC, blood biochemistry tests and clinical characteristics were combined as whole in this study to comprehensively characterize the survival status of mNPC. Classical machine learning techniques were employed to construct prognostic models and evaluate the prognostic capabilities of the combined factors (called features herein) on the models. A subset of features was obtained to achieve the best prognostic performance of patient survival patterns. Patients were dichotomized into two subgroups based on their median OS. Therefore, survival pattern analysis for mNPC was transformed to a binary classification problem, and the SVM model was used to construct prognostic classification models. The clinical parameters were further pruned to a compact yet informative subset to investigate informative variables that could distinguish low-risk patients from high-risk patients. This process is known as feature subset selection (FSS) [23-25], and we used the well-known Recursive Feature Elimination procedure based on SVM (RFE-SVM). The optimal subset with acceptable prognostic capabilities was obtained, and the SVM model was tested using a ten-fold cross-validation scheme. The entire patient set was randomly divided into ten equal-sized groups in the ten-fold cross-validation model. Nine groups were used for model construction in each experiment, and the last group
was used to test the model performance. The experiment was iterated until every group was tested, and the averaged performance was recorded to quantify the prognostic performance of the model.

**FUNDING**

This work was supported by grants from National Natural Science Foundation of China (No.81572912 and No.81201103), New Century Excellent Talents in University (NCET-12-0562), Guangdong public welfare research and capacity building projects (2014B020212005), Guangdong Provincial Natural Science Foundation in China (S2013020012726), the Program of Sun Yat-Sen University for Clinical Research 5010 Program (No.201310 and No. 2015011), Major project of Sun Yat-Sen University for the new cross subject, and Special support program for High-level talents in Sun Yat-Sen University Cancer Center (to M.Y. Chen).

**CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest.

**REFERENCES**

1. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer. 1996; 77: 2423-2431.
2. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, Tung SY, Thaw M, Ho JH. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 23: 261-270.
3. Sham JS, Choy D, Choi PH. Nasopharyngeal carcinoma: the significance of neck node involvement in relation to the pattern of distant failure. Br J Radiat Oncol Biol Phys. 1992; 23: 261-270.
4. Loong HH, Ma BB, Chan AT. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. Hematol Oncol Clin North Am. 2008; 22: 1267-1278.
5. Khanfir A, Frikha M, Ghorbel A, Karray H, Drira MM, Daoud J. [Metastatic nasopharyngeal carcinoma: clinical study and therapeutic results of 95 cases]. Cancer Radiother. 2006; 10: 545-549.
6. Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D, Sze WM, Law CK, Leung TW, Chan AT. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer. 2004; 101: 300-306.
7. Chen MY, Jiang R, Guo L, Zou X, Liu Q, Sun R, Qiu F, Xia ZJ, Huang HQ, Zhang L, Hong MH, Mai HQ, Qian CN. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chin J Cancer. 2013; 32: 604-613.
8. Jin Y, Cai XY, Cai YC, Cao Y, Xia Q, Tan YT, Jiang WQ, Shi YX. To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area. Eur J Cancer. 2012; 48: 882-888.
9. Ong YK, Heng DM, Chung B, Leong SS, Wee J, Fong KW, Tan T, Tan EH. Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer. 2003; 39: 1535-1541.
10. Sentelle CG, Anagnostopoulos GC, Georgiopoulos M. A Simple Method for Solving the SVM Regularization Path for Semidefinite Kernels. IEEE Trans Neural Netw Learn Syst. 2015.
11. Kim H, Lee S, Lee D, Choi S, Ju J, Myung H. Real-Time Human Pose Estimation and Gesture Recognition from Depth Images Using Superpixels and SVM Classifier. Sensors (Basel). 2015; 15: 12410-12427.
12. Chen HL, Yang B, Wang G, Wang SJ, Liu J, Liu DY. Support vector machine based diagnostic system for breast cancer using swarm intelligence. J Med Syst. 2012; 36: 2505-2519.
13. Zhang H, Yu P, Xiang ML, Li XB, Kong WB, Ma JY, Wang JL, Zhang JP, Zhang J. Prediction of drug-induced eosinophilia adverse effect by using SVM and naive Bayesian approaches. Med Biol Eng Comput. 2015.
14. Xu W, Yan G, Wang Z, Liu G, Kuang S, Zhao S. [A method for bleeding detection in endoscopy images using SVM]. Zhongguo Yi Liao Qi Xie Za Zhi. 2015; 39: 9-12.
15. Li YH, Wang FH, Jiang WQ, Xiang XJ, Deng YM, Hu GQ, Xu DM, Chen Y, Lin Q, He YJ. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2008; 62: 539-544.
16. Tan EH, Khoo KS, Lee JY, Kwong W, Lee KM, Chua ET, Tan T, Khoo-Tan HS, Yang TL, Au E, Tao M, Ong YK, Chua EJ. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999; 10: 235-237.
17. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358: 966-970.
18. Flanagan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JJ, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345: 1655-1659.
19. Morgan SC, Parker CC. Local treatment of metastatic cancer—killing the seed or disturbing the soil? Nat Rev Clin Oncol. 2011; 8: 504-506.

20. Lin S, Tham IW, Pan J, Han L, Chen Q, Lu JJ. Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer. Am J Clin Oncol. 2012; 35: 474-479.

21. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ, Zhao C. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 2011; 117: 1874-1883.

22. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011; 80: 661-668.

23. Berdouses ED, Koutsouri GD, Tripoliti EE, Matsopoulos GK, Oulis CJ, Fotiadis DI. A computer-aided automated methodology for the detection and classification of occlusal caries from photographic color images. Comput Biol Med. 2015; 62: 119-135.

24. Guinness RE. Beyond where to how: a machine learning approach for sensing mobility contexts using smartphone sensors. Sensors (Basel). 2015; 15: 9962-9985.

25. Rahman Q, Tereshchenko L, Kongkatong M, Abraham T, Abraham M, Shatkay H. Utilizing ECG-based Heartbeat Classification for Hypertrophic Cardiomyopathy Identification. IEEE Trans Nanobioscience. 2015.